Treats relapsing forms of multiple sclerosis. ANDA 209572, held by Alembic. Teriflunomide.
As of Nov 16, 2026, ANDA 209572 (Teriflunomide), held by Alembic, was first approved by FDA on Apr 19, 2019, with 4 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 19, 2019 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Oct 7, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 7, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 9, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 19, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters